{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960285",
  "id": "02960285",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250620",
  "time": "0836",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06kxwnhnd4h5k9.pdf",
  "summary": "### Key Material Information:  \n- **US Commercial Launch**: PromarkerD (predictive blood test for diabetic kidney disease) launched in the US at the American Diabetes Association Scientific Sessions (20\u201323 June 2025).  \n- **Initial Market Focus**: California, via Proteomics International\u2019s CLIA-certified laboratory.  \n- **Market Opportunity**: Targets over 32 million US adults with diabetes; addresses $130B annual DKD healthcare costs.  \n- **Commercial Strategy**: Hybrid model (direct-to-consumer and partnerships); supports potential licensing/distribution discussions.  \n- **Australian Rollout**: Pilot in WA/NT; nationwide expansion pending NATA accreditation.  \n\n*No capital raising, financials, or trading-sensitive dates identified.*",
  "usage": {
    "prompt_tokens": 2199,
    "completion_tokens": 151,
    "total_tokens": 2350,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T22:52:59.441049"
}